Association of Cystatin C with Metabolic Syndrome and Its Prognostic Performance in Non-ST-Segment Elevation Acute Coronary Syndrome with Preserved Renal Function

Joint Authors

Zheng, Wei
Li, Youmei
Li, Lufeng
Mao, Qi
Zhao, Xiaohui
Zhao, Ning
Wang, Yuqing
Xiang, Chaojun
Xu, Shangcheng

Source

BioMed Research International

Issue

Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-11, 11 p.

Publisher

Hindawi Publishing Corporation

Publication Date

2019-06-16

Country of Publication

Egypt

No. of Pages

11

Main Subjects

Medicine

Abstract EN

Objective.

The underlying mechanisms by which cystatin C affects cardiovascular disease (CVD) are not very clear.

Metabolic syndrome (MetS) is a cluster of risk factors that increase the risk of CVD.

Here, we aimed to investigate the association of cystatin C with metabolic syndrome and cardiovascular outcomes in non-ST-segment elevation acute coronary syndrome (NSTE-ACS) with preserved renal function.

Methods.

In total, 422 NSTE-ACS patients with preserved renal function were enrolled to examine the association of cystatin C with MetS.

MetS was defined based on the NCEP-ATP-III guidelines.

Major adverse cardiovascular events (MACEs) were also evaluated, which included cardiac death, nonfatal myocardial infarction (MI), target vessel revascularization (TVR), heart failure, and nonfatal stroke.

All patients underwent a 12-month follow-up for MACEs after admission.

Results.

Cystatin C was significantly correlated with metabolic risk factors and inflammation markers.

The prevalence of MetS and MACEs correlated with cystatin C levels.

Cystatin C showed a strong diagnostic performance for cardiovascular risk factors and outcomes in ROC analysis.

After adjustment for multiple risk factors, cystatin C level was independently associated with MetS (OR 2.299, 95% CI 1.251–4.225, and P = 0.007).

During a 12-month follow-up, the patients with high cystatin C level and MetS had higher incidence of MACEs (Log-rank = 24.586, P < 0.001) and cardiac death (Log-rank = 9.890, P = 0.020) compared to the others.

Multivariate Cox analysis indicated that cystatin C level was an independent predictor of MACEs (HR 2.609, 95% CI 1.295–5.257, and P = 0.007).

Conclusion.

Cystatin C may be an independent predictor of metabolic syndrome and therefore valuable for management of NSTE-ACS patients.

Further multicenter, large-scale studies are required to assess the implication of these results.

American Psychological Association (APA)

Mao, Qi& Zhao, Ning& Wang, Yuqing& Li, Youmei& Xiang, Chaojun& Li, Lufeng…[et al.]. 2019. Association of Cystatin C with Metabolic Syndrome and Its Prognostic Performance in Non-ST-Segment Elevation Acute Coronary Syndrome with Preserved Renal Function. BioMed Research International،Vol. 2019, no. 2019, pp.1-11.
https://search.emarefa.net/detail/BIM-1127968

Modern Language Association (MLA)

Mao, Qi…[et al.]. Association of Cystatin C with Metabolic Syndrome and Its Prognostic Performance in Non-ST-Segment Elevation Acute Coronary Syndrome with Preserved Renal Function. BioMed Research International No. 2019 (2019), pp.1-11.
https://search.emarefa.net/detail/BIM-1127968

American Medical Association (AMA)

Mao, Qi& Zhao, Ning& Wang, Yuqing& Li, Youmei& Xiang, Chaojun& Li, Lufeng…[et al.]. Association of Cystatin C with Metabolic Syndrome and Its Prognostic Performance in Non-ST-Segment Elevation Acute Coronary Syndrome with Preserved Renal Function. BioMed Research International. 2019. Vol. 2019, no. 2019, pp.1-11.
https://search.emarefa.net/detail/BIM-1127968

Data Type

Journal Articles

Language

English

Notes

Includes bibliographical references

Record ID

BIM-1127968